{"id":10040,"date":"2013-10-15T08:04:16","date_gmt":"2013-10-15T12:04:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=10040"},"modified":"2013-10-15T05:02:42","modified_gmt":"2013-10-15T09:02:42","slug":"mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040","title":{"rendered":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/14\/2013 (wallstreetpr) &#8211;\u00a0 For the sake of humanity,\u00a0MannKind Corporation (NASDAQ:MNKD) which so far has no drug on the market hopes its candidate Afrezza will this time get the approval of the Food and Drug Administration (FDA).<\/p>\n<p style=\"text-align: justify;\">\u00a0The company on Monday announced resubmitting of new drug application to FDA for the drug candidate which might turn out to be the much needed solution for adults with diabetes.<\/p>\n<p style=\"text-align: justify;\">MNKD\u2019s Afrezza is a fast-acting inhaler insulin powder contained in cartridge delivery. First application for approval of this drug was in March 2009. But in 2011, FDA asked for further clinical study on this adult diabetes drug. The reason FDA sent Afrezza back to the manufacturer for more trial was to compare the drugs efficacy with the previous inhalers which had been submitted for approval. History shows that FDA is quite strict when it comes to approval of inhaled insulin and many drugs have fallen casualty to this strictness of the approving agency.<\/p>\n<p style=\"text-align: justify;\">\u00a0From 2011 when FDA returned a \u201cfurther trial note\u201d to MNKD, the drug manufacturer in August this year announced that the drug has met its two trial objectives.<\/p>\n<p style=\"text-align: justify;\">In the latest Afrezza study, one set of patients around 171 were tried for type-1 diabetes and another set of around 175 patients were tried for type-2 diabetes. Therefore the new application includes data from these two successful trials, raising chances for the drug\u2019s approval.<\/p>\n<p style=\"text-align: justify;\">As more cases of obesity are linked to rise in diabetes, there is a growing demand for drugs that treat diabetes. But several drug developers have failed in their attempts with inhaled insulin for adult diabetes condition. This is why MNKD may run into good sales and profits if the drug gets the FDA nod.<\/p>\n<p style=\"text-align: justify;\">The performance of MNKD shares on Monday reveals growing optimism in the stock which can be link higher belief that Afrezza will be approved this time round. MNKD has a market cap of $1.60 billion as of Monday, October 14, 2013.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/14\/2013 (wallstreetpr) &#8211;\u00a0 For the sake of humanity,\u00a0MannKind Corporation (NASDAQ:MNKD) which so far has no drug on the market hopes its candidate Afrezza [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":10041,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3395,2246,3396,2247],"stock_ticker":[],"class_list":["post-10040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-mannkind-corporation","tag-mannkind-corporation-nasdaqmnkd","tag-mnkd","tag-nasdaqmnkd","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/14\/2013 (wallstreetpr) &#8211;\u00a0 For the sake of humanity,\u00a0MannKind Corporation (NASDAQ:MNKD) which so far has no drug on the market hopes its candidate Afrezza [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-15T12:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time\",\"datePublished\":\"2013-10-15T12:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg\",\"keywords\":[\"MannKind Corporation\",\"MannKind Corporation (NASDAQ:MNKD)\",\"MNKD\",\"NASDAQ:MNKD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\",\"name\":\"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg\",\"datePublished\":\"2013-10-15T12:04:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040","og_locale":"en_US","og_type":"article","og_title":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR","og_description":"Boston, MA 10\/14\/2013 (wallstreetpr) &#8211;\u00a0 For the sake of humanity,\u00a0MannKind Corporation (NASDAQ:MNKD) which so far has no drug on the market hopes its candidate Afrezza [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-10-15T12:04:16+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time","datePublished":"2013-10-15T12:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg","keywords":["MannKind Corporation","MannKind Corporation (NASDAQ:MNKD)","MNKD","NASDAQ:MNKD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040","url":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040","name":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg","datePublished":"2013-10-15T12:04:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/84.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/mannkind-corporation-nasdaqmnkd-hopes-fda-gives-afrezza-nod-this-time-10040#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"MannKind Corporation (NASDAQ:MNKD) Hopes FDA Gives Afrezza Nod This Time"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/10040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=10040"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/10040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/10041"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=10040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=10040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=10040"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=10040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}